Phase 3 Obesity Trial, Recruiting NCT07575399 Sponsor: Amgen Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT07575399
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with a Body Mass Index (BMI) of 25 or higher at the time of screening (BMI is a measure of body weight relative to height)
  • People who have already lost 10% or more of their body weight while taking a weekly GLP-1 RA medication (a type of weight management injection)
  • People whose body weight has been steady and not changing significantly
  • People who have been taking their GLP-1 RA medication at the same dose for a consistent period
  • People who have been tolerating their GLP-1 RA medication without ongoing stomach or digestive problems
  • Women who are using an accepted form of contraception
  • People who are willing to follow all trial procedures for the full length of the trial

Who may not be able to join:

  • People whose weight condition is caused by another hormonal or gland-related disorder, such as Cushing's syndrome
  • People who have previously had, or are planning to have, surgery, an endoscopic procedure, or a medical device implanted to treat their weight
  • People with a history of cancer
  • People who have Type 1 or Type 2 diabetes
  • People who have a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer
  • People who have previously taken part in a clinical trial involving a medicine called Maridebart Cafraglutide

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: MD, Amgen

Phone: 866-572-6436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
11 May 2026
Est. completion
3 January 2028

Where this trial is recruiting

Puerto Rico 🇺🇸 United States

Primary endpoints

Percent Change from Baseline in Body Weight at Week 68

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov